Foghorn Therapeutics

Foghorn Therapeutics

Foghorn Therapeutics launched in 2015 from Flagship Pioneering, the venture-creation firm that built Moderna. Flagship incubated the company around discoveries in chromatin biology — the protein machinery that opens and closes DNA for transcription. Adrian Gottschalk, who joined from Avanir Pharmaceuticals, took the chief executive role and brought the company public on Nasdaq in October 2020 at a $16-per-share price. The underlying thesis holds that many cancers and degenerative diseases arise from broken chromatin-remodeling complexes, and that small molecules can correct those defects. Foghorn operates as a clinical-stage public biotechnology company rather than a family office or diversified asset manager. The platform, branded as the Gene Traffic Control system, maps hundreds of chromatin regulators and identifies points where disruption creates therapeutic windows. Preclinical and clinical programs span hematologic cancers, solid tumors, and genetically defined sarcomas. Lead asset FHD-286 targets the BAF chromatin-remodeling complex in acute myeloid leukemia; a Phase 1 dose-escalation study began in 2021. FHD-609, a BRD9 degrader for synovial sarcoma, entered the clinic the same year. Eli Lilly partnered with Foghorn in December 2021 in a deal that included a $300 million upfront payment and an equity investment, co-developing multiple oncology targets. The collaboration's first nominated target triggered a milestone payment in early 2025 (per the firm's official communications, 2025). Foghorn operates from Cambridge, Massachusetts, and employed roughly 100 people heading into 2025. The firm cut workforce by approximately 30% in early 2025 alongside a strategic re-prioritization that shelved FHD-286 in uveal melanoma to focus on hematology and Lilly-partnered programs. Its cash runway extends into mid-2027, supported by the Lilly upfront and follow-on financing. No external fund vehicles or co-investment clubs are reported — Foghorn accesses capital through public equity markets and biopharma partnerships, not through LP commitments or family-office structures. Foghorn's chief medical officer, Dr. Samuel Agresta, previously led clinical development at Infinity Pharmaceuticals. The firm's structural distinction is its exclusive focus on the chromatin regulatory system as a therapeutic target class. Most oncology drug platforms concentrate on kinases, immune checkpoints, or cell-surface antigens; Foghorn's dataset maps the protein machinery that physically opens DNA to expose oncogenic transcription programs. This requires proprietary biochemical assays and computational models of the BAF, COMPASS, and PRC complexes that do not exist in standard compound libraries. That narrow aperture creates concentration risk — the pipeline lives or dies on whether drugging BAF and BRD9 translates to durable human responses — but it also means Foghorn holds one of the few systematized chromatin-targeting libraries in biotech.